Skip to content

Study · Observational study · n = 111 · 2026

6 results

Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Savvidou S, Augousti-Varela E, Damianakou A, Chalkias M, Stergiou I

Metabolic syndrome and related disorders20 Dec 2025

PMID41944572 (opens in a new tab)DOI10.1177/15578518251409025 (opens in a new tab)PepBankPUB-41944572
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and MASLD, semaglutide was followed by an overall HbA1c drop of 5.6% in real-world practice.

    In plain wordsIn adults with type 2 diabetes and fatty liver disease, HbA1c fell by 5.6% during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c drop
    Study

    n = 111

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5-2.4 mg/week · subcutaneous · median 12 monthsAs given in this study (human).

    Measurements

    HbA1c drop
    5.6%
    median

    Source sentences

    Summary
    an overall drop in HbA1c of 5.6% (IQR: 1.6-8.6)
    1 context sentence
    Summary · context
    A total of 111 patients were included: 31 males (27.9%), with a mean age 56.4 ± 9.7 years old, body mass index 32.7 ± 6.3 kg/m2, and median glycated hemoglobin (HbA1c) 5.8% (interquartile range [IQR]: 5.6-6.2).
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and MASLD, semaglutide was followed by a weight loss of 10% in real-world practice.

    In plain wordsIn adults with type 2 diabetes and fatty liver disease, body weight fell by 10% during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss
    Study

    n = 111

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5-2.4 mg/week · subcutaneous · median 12 monthsAs given in this study (human).

    Measurements

    Weight loss
    10%
    median

    Source sentences

    Summary
    weight loss of 10% (IQR: 3.2-19.6)
    1 context sentence
    Summary · context
    A total of 111 patients were included: 31 males (27.9%), with a mean age 56.4 ± 9.7 years old, body mass index 32.7 ± 6.3 kg/m2, and median glycated hemoglobin (HbA1c) 5.8% (interquartile range [IQR]: 5.6-6.2).
  3. 03HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and MASLD, all liver enzymes fell significantly after semaglutide treatment (p < 0.001).

    In plain wordsIn adults with type 2 diabetes and fatty liver disease, all liver enzymes fell significantly during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver enzymes
    Study

    n = 111

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.5-2.4 mg/week · subcutaneous · median 12 monthsAs given in this study (human).

    Source sentences

    Summary
    statistically significant reductions were recorded in all liver enzymes and elastographic parameters (p < 0.001).
    1 context sentence
    Summary · context
    A total of 111 patients were included: 31 males (27.9%), with a mean age 56.4 ± 9.7 years old, body mass index 32.7 ± 6.3 kg/m2, and median glycated hemoglobin (HbA1c) 5.8% (interquartile range [IQR]: 5.6-6.2).
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes and MASLD on semaglutide, weight loss independently predicted improvements in aminotransferases and controlled attenuation parameter, irrespective of treatment duration and baseline FIB-4.

    In plain wordsIn adults with type 2 diabetes and fatty liver disease on semaglutide, weight loss, not treatment length, predicted better liver enzymes and liver fat results.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeight loss as predictor of aminotransferase and CAP improvement
    Study

    n = 111

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.5-2.4 mg/week · subcutaneous · median 12 monthsAs given in this study (human).

    Source sentences

    Summary
    In multiple regression analysis, weight loss was found to independently predict improvements in aminotransferases and measured CAP (p < 0.001), irrespective of treatment duration and baseline FIB-4.
    1 context sentence
    Summary · context
    A total of 111 patients were included: 31 males (27.9%), with a mean age 56.4 ± 9.7 years old, body mass index 32.7 ± 6.3 kg/m2, and median glycated hemoglobin (HbA1c) 5.8% (interquartile range [IQR]: 5.6-6.2).
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, MASLD and high FIB-4, elastographic liver stiffness fell significantly after semaglutide treatment (p < 0.001).

    In plain wordsIn adults with type 2 diabetes, fatty liver disease and a high scarring score, liver stiffness fell significantly during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseLiver stiffness measurement
    Study

    n = 35

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.5-2.4 mg/week · subcutaneous · median 12 monthsAs given in this study (human).

    Source sentences

    Summary
    statistically significant reductions were recorded in all liver enzymes and elastographic parameters (p < 0.001).
    2 context sentences
    Summary · context
    In participants with high FIB-4, elastographic liver stiffness measurements (LSM) and controlled attenuation parameter (CAP) were acquired with FibroScan® before and after treatment with semaglutide.
    Summary · context
    Thirty-three patients (29.7%) had aspartate aminotransferase and/or alanine aminotransferase above normal, and 35 (31.5%) high FIB-4 score.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, MASLD and high FIB-4, the controlled attenuation parameter fell significantly after semaglutide treatment (p < 0.001).

    In plain wordsIn adults with type 2 diabetes, fatty liver disease and a high scarring score, a liver fat measure fell significantly during semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseControlled attenuation parameter (steatosis)
    Study

    n = 35

    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.5-2.4 mg/week · subcutaneous · median 12 monthsAs given in this study (human).

    Source sentences

    Summary
    statistically significant reductions were recorded in all liver enzymes and elastographic parameters (p < 0.001).
    2 context sentences
    Summary · context
    In participants with high FIB-4, elastographic liver stiffness measurements (LSM) and controlled attenuation parameter (CAP) were acquired with FibroScan® before and after treatment with semaglutide.
    Summary · context
    Thirty-three patients (29.7%) had aspartate aminotransferase and/or alanine aminotransferase above normal, and 35 (31.5%) high FIB-4 score.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.